Sign In
Buy RAPT
$58.02
+0 (+0%)
At Close: Jun 01, 2026
GSK to buy RAPT Therapeutics for $2.2 billion
02:11am, Tuesday, 20'th Jan 2026
GSK said on Tuesday that it would acquire U.S.-based RAPT Therapeutics for $2.2 billion.
RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:45pm, Wednesday, 14'th Jan 2026
RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rapt Therapeutics (NASDAQ:RAPT) Shares Gap Up – Time to Buy?
03:26am, Sunday, 11'th Jan 2026
Shares of Rapt Therapeutics (NASDAQ: RAPT - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $31.20, but opened at $32.88. Rapt Therapeutics shares last traded
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 07'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an
Rapt Therapeutics (NASDAQ:RAPT) & Atea Pharmaceuticals (NASDAQ:AVIR) Head-To-Head Contrast
02:14am, Sunday, 28'th Dec 2025
Atea Pharmaceuticals (NASDAQ: AVIR - Get Free Report) and Rapt Therapeutics (NASDAQ: RAPT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the tw
RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices
07:32am, Saturday, 15'th Nov 2025
RAPT Therapeutics is upgraded to a 'Buy' due to promising pipeline progress and attractive valuation after a significant share price decline. Ozureprubart, RAPT's lead candidate, showed favorable phas
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
08:00am, Thursday, 06'th Nov 2025
- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
04:05pm, Tuesday, 04'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
08:00am, Monday, 27'th Oct 2025
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for t
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
11:12pm, Tuesday, 21'st Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering,
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 21'st Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering,
RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript
05:05pm, Monday, 20'th Oct 2025
RAPT Therapeutics, Inc. (NASDAQ:RAPT ) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Company Participants Sylvia Wheeler Brian Wong - CE
- RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing- Efficacy sustained at Week 16 after a single dose of RPT904- Well tolerated with no seriou
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
08:00am, Sunday, 19'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an
Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This
